RxDoctor Payments Data

Mackenzie Thomas

Nurse Practitioner · Hermitage, TNNPI 1730855735

Payments from drug & device makers

$11,428in general payments, 2019–2025

Across 473 payments — averaging $24.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$674
  • Regeneron Healthcare Solutions, Inc.$640
  • QOL Medical, LLC$547
  • plus $5K from 38 others

What the payments were for

  • Consulting fees$9158%
  • Food & beverage$10,26690%
  • Education$2132%
  • Other$340%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,428 in reported general payments places this provider in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$94,720
Medicare patients
255
Services billed
3,320

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SucraidSacrosidase15$206,284
XifaxanRifaximin26$80,140
ZenpepLipase/Protease/Amylase12$39,360
LinzessLinaclotide37$36,223
Mesalamine13$14,169
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C35$4,929
Budesonide DrBudesonide14$3,289
Colesevelam Hcl35$2,075
Pantoprazole Sodium119$1,985
Sucralfate44$1,597
Dicyclomine Hcl53$1,438
Esomeprazole Magnesium11$924
Omeprazole81$840
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates15$783
Ondansetron OdtOndansetron17$516

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
QOL Medical, LLCSucraid$547$206,28415 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$1,290$85,06961 claims
Aimmune Therapeutics, Inc.Zenpep$403$39,36012 claims
AbbVieLinzess$1,991$36,22337 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Hermitage

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →